Fibrinogen-like protein 2: a potential molecular target for glioblastoma treatment.
作者信息
Patel Rajan, Traylor Jeffrey I, Latha Khatri, Heimberger Amy B, Li Shulin, Rao Ganesh
机构信息
a Department of Neurosurgery , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
b Department of Pediatrics-Research , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
出版信息
Expert Opin Ther Targets. 2019 Aug;23(8):647-649. doi: 10.1080/14728222.2019.1628220. Epub 2019 Jun 5.
Abstract
摘要
相似文献
1
Fibrinogen-like protein 2: a potential molecular target for glioblastoma treatment.
Expert Opin Ther Targets. 2019 Aug;23(8):647-649. doi: 10.1080/14728222.2019.1628220. Epub 2019 Jun 5.
2
FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas.
J Natl Cancer Inst. 2015 May 13;107(8). doi: 10.1093/jnci/djv137. Print 2015 Aug.
3
Clonal diversity in glioblastoma: is it clinically relevant?
Future Oncol. 2015;11(12):1703-6. doi: 10.2217/fon.15.73.
4
Fibrinogen-like protein 2: Its biological function across cell types and the potential to serve as an immunotherapy target for brain tumors.
Cytokine Growth Factor Rev. 2023 Feb;69:73-79. doi: 10.1016/j.cytogfr.2022.08.004. Epub 2022 Sep 2.
5
Extracellular Vesicles in Glioma: From Diagnosis to Therapy.
Bioessays. 2019 Jul;41(7):e1800245. doi: 10.1002/bies.201800245. Epub 2019 Jun 12.
6
Functional validation confirms genomic phenotypes of glioblastoma with implications for targeted therapy.
World Neurosurg. 2011 May-Jun;75(5-6):573-4. doi: 10.1016/j.wneu.2011.03.029.
7
Glioblastoma multiforme: introduction.
Cancer J. 2003 Mar-Apr;9(2):71. doi: 10.1097/00130404-200303000-00001.
8
Atypical presentation and progression of glioblastoma multiforme in a 6-year-old girl: multidisciplinary case report.
J Pediatr Hematol Oncol. 2003 Mar;25(3):243-7. doi: 10.1097/00043426-200303000-00012.
9
Long-term survival after glioblastoma multiforme.
South Med J. 2008 Sep;101(9):971-2. doi: 10.1097/SMJ.0b013e31818005e5.
10
Current and future novel treatments for glioblastoma multiforme.
Biomed Res Int. 2014;2014:432195. doi: 10.1155/2014/432195. Epub 2014 Dec 22.
引用本文的文献
1
Targeting FGL2 in glioma immunosuppression and malignant progression.
Front Oncol. 2022 Oct 13;12:1004700. doi: 10.3389/fonc.2022.1004700. eCollection 2022.
2
The role of Fibrinogen-like proteins in Cancer.
Int J Biol Sci. 2021 Mar 8;17(4):1079-1087. doi: 10.7150/ijbs.56748. eCollection 2021.
3
Tumor-associated macrophage polarization promotes the progression of esophageal carcinoma.
Aging (Albany NY). 2020 Dec 15;13(2):2049-2072. doi: 10.18632/aging.202201.
本文引用的文献
1
FGL2 promotes tumor progression in the CNS by suppressing CD103 dendritic cell differentiation.
Nat Commun. 2019 Jan 25;10(1):448. doi: 10.1038/s41467-018-08271-x.
2
PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma.
Neurology. 2018 Oct 2;91(14):e1355-e1359. doi: 10.1212/WNL.0000000000006283. Epub 2018 Aug 31.
3
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
N Engl J Med. 2018 Aug 23;379(8):722-730. doi: 10.1056/NEJMoa1805453.
4
The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma.
J Natl Cancer Inst. 2019 Mar 1;111(3):292-300. doi: 10.1093/jnci/djy107.
5
Inhibition of the Fibrinogen-Like Protein 2:FcγRIIB/RIII immunosuppressive pathway enhances antiviral T-cell and B-cell responses leading to clearance of lymphocytic choriomeningitis virus clone 13.
Immunology. 2018 Jul;154(3):476-489. doi: 10.1111/imm.12897. Epub 2018 Feb 20.
6
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143.
Neuro Oncol. 2018 Apr 9;20(5):674-686. doi: 10.1093/neuonc/nox208.
7
Modulating glioma-mediated myeloid-derived suppressor cell development with sulforaphane.
PLoS One. 2017 Jun 30;12(6):e0179012. doi: 10.1371/journal.pone.0179012. eCollection 2017.
8
Prospects of immune checkpoint modulators in the treatment of glioblastoma.
Nat Rev Neurol. 2015 Sep;11(9):504-14. doi: 10.1038/nrneurol.2015.139. Epub 2015 Aug 11.
9
FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas.
J Natl Cancer Inst. 2015 May 13;107(8). doi: 10.1093/jnci/djv137. Print 2015 Aug.
10
Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity.
Cancer Cell. 2014 Nov 10;26(5):638-52. doi: 10.1016/j.ccell.2014.09.007. Epub 2014 Oct 16.
Zotero 插件